{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Anemia, Any Grade Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Anemia, Increase to Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Anemia, Increase to Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Hemoglobin increased, Any Grade Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Hemoglobin increased, Increase to Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Hemoglobin increased, Increase to Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Leukocytosis, Any Grade Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Leukocytosis, Increase to Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Leukocytosis, Increase to Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"WBC decreased, Any Grade Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"WBC decreased, Increase to Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"WBC decreased, Increase to Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Lymphocyte count decreased, Any Grade Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Lymphocyte count decreased, Increase to Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Lymphocyte count decreased, Increase to Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Lymphocyte count increased, Any Grade Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Lymphocyte count increased, Increase to Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Lymphocyte count increased, Increase to Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Neutrophil count decreased, Any Grade Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Neutrophil count decreased, Increase to Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Neutrophil count decreased, Increase to Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"Platelet count decreased, Any Grade Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Platelet count decreased, Increase to Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Platelet count decreased, Increase to Grade 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"Blood samples were collected for the analysis of following hematology parameters: hemoglobin, White blood cell (WBC) count, lymphocytes, neutrophils and platelet. The laboratory parameters were graded according to NCI-CTCAE version 4.03. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Any worst case post baseline increase in grade along with any increase to a maximum grade of 3 and a maximum grade of 4 are presented.","groups":[{"description":"Participants were administered belantamab mafodotin with recommended phase 2 dose (RP2D) of 2.5 mg/kg in combination with 200 mg of pembrolizumab via IV infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles.","id":"OG000","title":"Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to approximately 178 weeks","title":"Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters","type":"SECONDARY","unitOfMeasure":"Participants"}